Original articleRapamycin confers preconditioning-like protection against ischemia–reperfusion injury in isolated mouse heart and cardiomyocytes
Introduction
Since the initial findings by Murry et al. [1] that brief episodes of ischemia can paradoxically protect the heart from subsequent ischemic injury, many investigators have tried to discover a pharmacological solution to ischemic preconditioning (IPC). IPC works by activating endogenous protective mechanisms and is realized in two phases: the early phase, which lasts up to 2–3 h, and a late phase, which appears 12–24 h later with duration of up to 3–4 days. Considerable progress has been made toward identifying cellular triggers and signal transduction mechanisms involved in the process of preconditioning and many pharmacological agents have been shown to induce a preconditioning-like effect [2], [3]. However, despite significant advances in this field, no agent has yet gained widespread clinical use [4]. In the present study, we demonstrate a novel approach of preconditioning the heart by using rapamycin, an increasingly widespread staple of cardiac practice.
Rapamycin (sirolimus) is an antibiotic derived from Streptomyces hygroscopius, and for many years has been primarily used as an immunosuppressant in the treatment of organ rejection in transplant recipients [5]. Recently, rapamycin's antigrowth properties have been utilized for cardiovascular benefit as stents impregnated with rapamycin effectively reduce coronary restenosis [6]. The proposed mechanism for the antiproliferative effect of rapamycin is based on its ability to bind to its intracellular receptor, the FK506 binding protein (FKBP12) [7]. The rapamycin/FKBP12 complex is an inhibitor of the mammalian target of rapamycin (mTOR), a 290-kDa Ser/Thr kinase that controls mammalian protein translational processes that are central to cell growth [8]. Rapamycin prevents DNA and protein synthesis, in large part, by regulation of p70S6 kinase (p70S6K) phosphatase, leading to arrest of the cell cycle at the G1/S interface [9]. Additionally, rapamycin modulation of the mTOR kinase plays key roles in nutrient regulation [10], mitochondrial metabolism [11], [12], and growth-factor stimulated proliferation [9], [13].
In a short time, rapamycin-eluting stents have become a vital tool for native coronary artery revascularization and also demonstrate favorable outcomes for treatment of saphenous vein graft lesions [14] and in-stent restenosis [15]. Furthermore, rapamycin taken orally has also shown promise as a potential agent to inhibit restenosis after stenting of de novo coronary lesions [16], [17], [18] as well as slow down the progression of coronary artery disease in heart transplant recipients [19]. Although, the antigrowth effect of rapamycin on vascular tissue has been widely described [8], the full spectrum of action of rapamycin, particularly on cardiac tissue, is not known.
Chemical preconditioning with some immunosuppressants has been shown in the heart [20], brain [21], and liver [22]; however, the cardioprotective effect of rapamycin is unknown [23], [24], [25], [26]. In the present study, we show, for the first time, that rapamycin induces a preconditioning-like protective effect in the intact heart and adult cardiomyocyte subjected to ischemia/reperfusion. Furthermore, our results show that rapamycin-induced cardioprotection is mediated by opening of the mitochondrial ATP-sensitive potassium channel (mitoKATP channel).
Section snippets
Animals
Adult male outbred ICR mice were supplied by Harlan Inc. (Indianapolis, IN). Animal experimental protocols were approved by the Institutional Animal Care and Use Committee of Virginia Commonwealth University.
Drugs and chemicals
Rapamycin was purchased from Sigma-Aldrich (St. Loius, MO) and was dissolved in DMSO (Sigma-Aldrich) for intraperitoneal injection (final DMSO concentration < 1%). Unless specified otherwise, all other chemicals including 5-hydroxydecanoate (5-HD), trypan blue dye, and triphenyltetrazolium
Baseline cardiovascular function
The adult male ICR mice used in the present study weighed an average of 34.7 ± 0.9 g (n = 24). There was no significant difference in heart-weight/body-weight among the groups. Preischemic baseline values of the isolated perfused hearts are summarized in Table 1. Baseline function (developed force and rate–force product) was similar between the RAPA and DMSO pretreated groups. The DMSO pretreated group that received 5-HD infusion during stabilization (DMSO + 5-HD) had an elevated developed
Discussion
The use of rapamycin has greatly increased during the past few years with the introduction of rapamycin-eluting coronary stents. The antihypertrophic effects of rapamycin have been well described [8]; however, other properties of this pharmacological agent are poorly understood. We report here our novel observation on the preconditioning-like effect of rapamycin in the mouse heart. More specifically, we have shown that intraperitoneal administration of rapamycin induces cardioprotection as
Conclusion
In summary, we have demonstrated, for the first time, that rapamycin induces preconditioning-like protective effects against myocardial infarction following ischemia–reperfusion injury through opening of mitoKATP channels. In addition, this drug reduced necrosis as well as apoptosis following simulated ischemia–reoxygenation injury in adult cardiomyocytes. We propose that the use of rapamycin may be a potentially novel therapeutic strategy to limit myocardial infarction and apoptosis following
Acknowledgments
The present study was supported in part by grants from National Institutes of Health (HL51045, HL59469, HL79424 to R.C.K) and American Heart Association, National Center (0530157N to L.X.).
References (81)
- et al.
Pharmacological preconditioning with sildenafil: basic mechanisms and clinical implications
Vascul. Pharmacol.
(2005) - et al.
TOR, a central controller of cell growth
Cell
(2000) - et al.
Treatment of saphenous vein graft lesions with drug-eluting stents: immediate and midterm outcome
J. Am. Coll. Cardiol.
(2005) - et al.
Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: the Oral Rapamune to Inhibit Restenosis (ORBIT) study
J. Am. Coll. Cardiol.
(2004) - et al.
Second window of protection following myocardial preconditioning: an essential role for PI3 kinase and p70S6 kinase
J. Mol. Cell Cardiol.
(2003) - et al.
Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling
J. Biol. Chem.
(2005) - et al.
Mitochondrial KATP channels in preconditioning
J. Mol. Cell Cardiol.
(2003) - et al.
Exogenous nitric oxide can trigger a preconditioned state through a free radical mechanism, but endogenous nitric oxide is not a trigger of classical ischemic preconditioning
J. Mol. Cell Cardiol.
(2000) - et al.
Aortic eNOS expression and phosphorylation in Apo-E knockout mice: differing effects of rapamycin and simvastatin
Surgery
(2004) - et al.
High local production of nitric oxide as a possible mechanism by which rapamycin prevents transplant arteriosclerosis
Transplant Proc.
(1998)
The ischemia-selective KATP channel antagonist, 5-hydroxydecanoate, blocks ischemic preconditioning in the rat heart
J. Mol. Cell Cardiol.
Mitochondrial KATP channel as an end effector of cardioprotection during late preconditioning: triggering role of nitric oxide
J. Mol. Cell Cardiol.
Reactive oxygen species released from mitochondria during brief hypoxia induce preconditioning in cardiomyocytes
J. Biol. Chem.
Adenosine A1 receptor activation reduces reactive oxygen species and attenuates stunning in ventricular myocytes
J. Mol. Cell Cardiol.
Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21(Cip1)
Mol. Cell
Rapamycin increases the cellular concentration of the BCL-2 protein and exerts an anti-apoptotic effect
Eur. J. Cancer
TSC2 mediates cellular energy response to control cell growth and survival
Cell
Interferon alpha-induced apoptosis in tumor cells is mediated through the phosphoinositide 3-kinase/mammalian target of rapamycin signaling pathway
J. Biol. Chem.
Adult cardiac stem cells are multipotent and support myocardial regeneration
Cell
Persistent expression of the ATP-binding cassette transporter, Abcg2, identifies cardiac SP cells in the developing and adult heart
Dev. Biol.
Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases
Cell
Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium
Circulation
Preconditioning the myocardium: from cellular physiology to clinical cardiology
Physiol. Rev.
Myocardial protection at a crossroads: the need for translation into clinical therapy
Circ. Res.
Prevention and treatment of allograft rejection in vivo by rapamycin: molecular and cellular mechanisms of action
Ann. N. Y. Acad. Sci.
A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization
N. Engl. J. Med.
Cellular functions of immunophilins
Physiol. Rev.
Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells
Circ. Res.
The TOR signaling cascade regulates gene expression in response to nutrients
Genes Dev.
FKBP12-rapamycin-associated protein associates with mitochondria and senses osmotic stress via mitochondrial dysfunction
Proc. Natl. Acad. Sci. U. S. A.
Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake
Mol. Biol. Cell
Different inhibitory effects of immunosuppressive drugs on human and rat aortic smooth muscle and endothelial cell proliferation stimulated by platelet-derived growth factor or endothelial cell growth factor
J. Heart Lung Transplant
Sirolimus-eluting stents vs. vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial
JAMA
Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial
Circulation
Role of oral rapamycin to prevent restenosis in patients with de novo lesions undergoing coronary stenting: results of the Argentina single centre study (ORAR trial)
Heart
Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial
Circulation
Pharmacological preconditioning of primary rat cardiac myocytes by FK506
Basic Res. Cardiol.
Immunophilins mediate the neuroprotective effects of FK506 in focal cerebral ischaemia
Nature
Effective prevention of ischemic injury of the dearterialized canine liver by FK506 pretreatment
Transplantation
Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling
Circ. Res.
Cited by (175)
Mammalian Target of Rapamycin Inhibition in Patients With ST-Segment Elevation Myocardial Infarction
2022, Journal of the American College of CardiologyInduction of JAK2/STAT3 pathway contributes to protective effects of different therapeutics against myocardial ischemia/reperfusion
2022, Biomedicine and PharmacotherapymTOR pathway: A potential therapeutic target for spinal cord injury
2022, Biomedicine and PharmacotherapyTrehalose preconditioning for transient global myocardial ischemia in rats
2021, Biochemical and Biophysical Research CommunicationsIschemia-reperfusion injury
2021, Organ Repair and Regeneration: Preserving Organs in the Regenerative Medicine EraDiclofenac impairs autophagic flux via oxidative stress and lysosomal dysfunction: Implications for hepatotoxicity
2020, Redox BiologyCitation Excerpt :Autophagy is one of the major routes for the clearance of aggregate-prone proteins or damaged organelles. Therefore, rapamycin treatment facilitates the clearance of abnormal proteins or mitochondria by autophagy and make the cells more resistant to toxic stimuli [54,55]. The protective effects of rapamycin can also be attributed to the regulation of the transcription of genes involved in mitochondrial redox homeostasis, such as RORC1, YY1 and PGC1α [56].
- 1
These authors contributed equally.